REVIEW(S)
Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials

https://doi.org/10.1016/S1081-1206(10)60004-XGet rights and content

Objectives

To evaluate the efficacy of sublingual immunotherapy (SLIT) in the treatment of allergic rhinitis in children.

Data Sources

A comprehensive search of the EMBASE, MEDLINE, LILACS, and CINAHL databases from January 1966 to February 10, 2006, was performed.

Study Selection

Randomized, double-blind, placebo-controlled trials of SLIT in the treatment of allergic rhinitis in patients 18 years or younger were selected. Outcomes measured were symptom scores and rescue medication use. Analysis was performed with standardized mean differences (SMDs) and a random-effects model.

Results

Seventy articles were identified and reviewed. Ten studies, published between 1990 and 2004, fulfilled the selection criteria. Five hundred seventy-seven patients were initially included in the studies. Of these patients, 484 (245 SLIT and 239 placebo) had a final clinical evaluation and could be evaluated. A relevant heterogeneity due to widely differing scoring systems was found. Overall, there was a significant reduction in both symptoms (SMD, 0.56, 95% confidence interval, 1.01–0.10; P = .02) and medication use (SMD, 0.76; 95% confidence interval, 1.46–0.06; P = .03) after immunotherapy. The subanalyses performed for treatment duration and type of allergen showed that SLIT for more than 18 months and with pollen extracts was effective compared with SLIT courses shorter than 18 months and with mites.

Conclusions

The results of this meta-analysis showed that, compared with placebo, SLIT with standardized extracts is effective in pediatric patients with allergic rhinitis.

REFERENCES (48)

  • J Bousquet et al.

    WHO position paper: allergen immunotherapy: therapeutic vaccines for allergic diseases

    Allergy

    (1998)
  • C Bachert et al.

    The WHO ARIA (Allergic Rhinitis and Its Impact on Asthma) initiative

    Chem Immunol Allergy

    (2003)
  • MS Khinchi et al.

    Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

    Allergy

    (2004)
  • G Passalacqua et al.

    Sublingual immunotherapy: an update

    Curr Opin Allergy Clin Immunol

    (2004)
  • C Baena-Cagnani et al.

    Sublingual immunotherapy in pediatric patients: beyond clinical efficacy

    Curr Opin Allergy Clin Immunol

    (2005)
  • GB Gidaro et al.

    The safety of sublingual-swallow immunotherapy: an analysis of published studies

    Clin Exp Allergy

    (2005)
  • J Bousquet

    Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms

    Allergy

    (2005)
  • H Malling et al.

    Immunotherapy: position paper of the European Academy of Allergy and Clinical Immunology

    Allergy

    (1993)
  • V Di Rienzo et al.

    Post-marketing surveillance study on the safety of sublingual immunotherapy in children

    Allergy

    (1999)
  • C Lombardi et al.

    Safety of sublingual immunotherapy in adults: a post marketing surveillance study

    Allergy

    (2001)
  • M Plaut et al.

    Clinical practice: allergic rhinitis

    N Engl J Med

    (2005)
  • DR Wilson et al.

    Sublingual immuno-therapy for allergic rhinitis: systematic review and meta-analysis

    Allergy

    (2005)
  • JM Olaguíbel et al.

    Efficacy of sublingual allergen vaccination for respiratory allergy in children: conclusions from one meta-analysis

    J Invest Allergol Clin Immunol

    (2005)
  • F Ippoliti et al.

    Immunomodulation during sublingual therapy in allergic children

    Pediatr Allergy Immunol

    (2003)
  • Cited by (0)

    Potential financial conflicts of interest: Dr Giorgio Walter Canonica and Dr G Passalacqua report having received research grants and lecture fees from the following: Alk-Abello, Anallergo, Allergy Therapeutics, A. Menarini, Almirall, Altana, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Genentech, Gentili, Glaxo Smith Kline, Lofarma, Merck Sharp & Dome, Novartis, Pfizer, Schering Plough, Stallergenes, and UCB Pharma.

    View full text